CADTH Canadian Drug Expert Committee recommendation: Nintedanib (Ofev -- Boehringer Ingelheim Canada Inc.) indication: chronic fibrosing interstitial lung diseases
The CADTH Canadian Drug Expert Committee recommends that nintedanib be reimbursed for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype only if certain conditions are met
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2021, February 26, 2021
|
| Edition: | Version 1.0 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee recommends that nintedanib be reimbursed for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype only if certain conditions are met |
|---|---|
| Physical Description: | 1 PDF file (8 pages) |